Please assess the completion status of the following clinical trial:

Trial Title: Telmisartan/Amlodipine (80/10) vs. Telmisartan/Amlodipine (40/10) vs. amlodipine10 in Resistant Hypertension

Study Design Characteristics:
- Allocation: None
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of essential hypertension and blood pressure not adequately controlled before informed consent (inadequate control defined as seated diastolic blood pressure (DBP) \>= 95 mmHg if on existing antihypertensive treatment or seated DBP \>= 100 mmHg if treatment-naïve).~* failure to respond to six weeks treatment with amlodipine 10mg. (Failure to respond defined as seated DBP \>= 90 mmHg.)~* able to stop any current antihypertensive therapy without unacceptable risk to the patient.~* willing and able to provide written informed consent.~Exclusion Criteria:~* pregnancy, breast-feeding, unwilling to use effective contraception (if female of child-bearing potential).~* known or suspected secondary hypertension.~* mean seated systolic blood pressure (SBP) \>=200 mmHg and/or mean seated DBP \>= 120 mmHg during run-in treatment or mean seated SBP \>= 180 mmHg and/or mean seated DBP \>= 120 mmHg at the randomisation visit or at any time during randomised treatment.~* any clinically significant hepatic impairment or severe renal impairment bilateral renal artery stenosis or renal artery stenosis in a solitary kidney or post post-renal transplant.~* clinically relevant hyperkalaemia.~* uncorrected volume or sodium depletion.~* primary aldosteronism.~* hereditary fructose or lactose intolerance.~* symptomatic congestive heart failure.~* patients who have previously experienced symptoms characteristic of angioedema during treatment with ACE inhibitors or ARBs.~* history of drug or alcohol dependency within the six months prior to signing consent.~* concurrent participation in another clinical trial or any investigational therapy within thirty days prior to signing consent.~* hypertrophic obstructive cardiomyopathy, hemodynamically relevant stenosis of the aortic or mitral valve.~* known allergic hypersensitivity to any component of the formulations under investigation. (Includes known hypersensitivity to telmisartan or other ARBs or amlodipine or other dihydropyridine CCBs.)~* non-compliance with study medication (defined as less than 80% or more than 120%) during the open-label run-in treatment period.~* current treatment with any antihypertensive agents, whether or not prescribed for this indication, that cannot be safely stopped (investigator¿s decision) by the start of the run-in period.~* chronic administration of any medication known to affect blood pressure, other than the trial medication.~* any other clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of telmisartan and amlodipine.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).